AI assistant
Sending…
Skye Bioscience, Inc. — Director's Dealing 2024
Mar 4, 2024
34097_dirs_2024-03-04_bb54e46d-14be-4a44-850b-75fd51faa481.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Skye Bioscience, Inc. (SKYE)
CIK: 0001516551
Period of Report: 2024-02-29
Reporting Person: DALESANDRO MARGARET (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-29 | Stock Option (Right to Buy) | $14.56 | A | 35000 | Acquired | 2034-03-01 | Common Stock (35000) | Direct |
Footnotes
F1: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024.
More from Skye Bioscience, Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
May 29
Delisting Announcement
2026
May 15
Annual Report
2026
Apr 16
Proxy Solicitation & Information Statement
2026
Apr 16
Board/Management Information
2026
Apr 3
Delisting Announcement
2026
Mar 19
Board/Management Information
2026
Feb 20
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Feb 10